医学
指南
肾脏疾病
恩帕吉菲
肾病科
重症监护医学
糖尿病
卡格列净
临床试验
内科学
肾
2型糖尿病
内分泌学
病理
作者
Alistair Roddick,Alexa Wonnacott,David R. Webb,Angela Watt,Michael A. Watson,Natalie Staplin,Alexandra Riding,Eirini Lioudaki,Apexa Kuverji,Mohsen El Kossi,Patrick Holmes,M C Holloway,Donald Fraser,Chris Carvalho,James O. Burton,Sunil Bhandari,William G. Herrington,Andrew Frankel
出处
期刊:BMC Nephrology
[Springer Nature]
日期:2023-10-25
卷期号:24 (1)
被引量:13
标识
DOI:10.1186/s12882-023-03339-3
摘要
Abstract Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full “lay” summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals.
科研通智能强力驱动
Strongly Powered by AbleSci AI